Teclistamab Appears Safe and Effective in Real-World Patients with Relapsed/Refractory Multiple Myeloma
Consult QD
DECEMBER 12, 2023
A real-world study confirms the efficacy of teclistamab in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM), including those with high-risk features of the disease. “The real-world experience demonstrates response rates comparable to those observed in the pivotal phase 2 MajesTEC-1 trial despite the inclusion of sicker patients who would not have been eligible for MajesTEC-1,” says Danai Dima, MD a hematology-oncology fellow at Cleveland Clinic, who is the principal i
Let's personalize your content